Know Cancer

or
forgot password

Feasibility Study Using the Xoft Axxent Electronic Brachytherapy System for the Treatment of Endometrial Cancer


N/A
18 Years
N/A
Not Enrolling
Female
Endometrial Cancer

Thank you

Trial Information

Feasibility Study Using the Xoft Axxent Electronic Brachytherapy System for the Treatment of Endometrial Cancer


Inclusion Criteria:



- Most types of endometrial (uterine) cancer Stage I and Stage II (see exclusion
criteria below)

- Post hysterectomy

Exclusion Criteria:

- Endometrial (uterine) cancer Stage IA Grade 1

- Scleroderma

- Collagen vascular disease

- Active Lupus

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Assess Number of Patients Who Were Able to Complete Treatment Delivery Using the Axxent Electronic Brachytherapy System

Outcome Time Frame:

through completion of radiation therapy

Safety Issue:

No

Principal Investigator

Adam Dickler, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Little Company of Mary

Authority:

United States: Institutional Review Board

Study ID:

TPR-0209

NCT ID:

NCT01045187

Start Date:

October 2008

Completion Date:

April 2010

Related Keywords:

  • Endometrial Cancer
  • endometrial cancer
  • Uterine cancer
  • electronic brachytherapy
  • Xoft
  • Endometrial Neoplasms
  • Sarcoma, Endometrial Stromal
  • Adenoma

Name

Location

Rhode Island HospitalProvidence, Rhode Island  02903
Swedish Covenant HospitalChicago, Illinois  60625
Little Company of Mary HospitalEvergreen Park, Illinois  60805
Cancer Treatment Services ArizonaCasa Grande, Arizona  85222
Southwest Oncology CenterPhoenix, Arizona  85251
Beverly Oncology & Imaging Medical Center, IncMontebello, California  90640